Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs Bodi Envi
Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
Published by The GLP-1 Verdict
Pricing sources checked: CoreAge Rx: August 2026 · Bodi Envi: Check date not recorded
vs
Verdict66/ 100
Grade C · #248Bodi Envi
Compounded-only telehealth selling semaglutide and tirzepatide at the same price at every dose, with no membership fee but an intro rate pushed by a countdown timer.
Visit Bodi EnviThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 66/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Bodi Envi still earns its place — buyers who want a genuinely flat all-dose compounded price and will ignore the intro-rate countdown.
The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results70
92
Real-world results70
97Price honesty60
97
Price honesty60
96Prescriber access70
96
Prescriber access70
88Formulary choice40
88
Formulary choice40
95Cancellation fairness80
95
Cancellation fairness80
93Member support80
93
Member support80
Price, coverage & features
| Metric | CoreAge Rx | Bodi Envi |
|---|---|---|
| Verdict Score | 94/100 | 66/100 |
| Grade | A | C |
| Semaglutide | $99/mo | $179/mo |
| Tirzepatide | $149/mo | $249/mo |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | No |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Bodi Envi
What we like
- Flat pricing at every dose: $179/mo semaglutide, $249/mo tirzepatide, stated verbatim as 'All doses'
- No consultation or membership fee charged on top of the monthly price
- Expedited shipping included; FSA and HSA eligible
- Cancel anytime, no long-term contract and no early-termination fee
- Micro-dose options and NAD+ injections ($130/mo flat) offered alongside the GLP-1s
The caveats
- Compounded semaglutide and tirzepatide are not FDA-approved finished products and have not been reviewed for safety, effectiveness or quality
- The $99 and $135 intro rates are presented with a 30-minute countdown timer, a pressure tactic; the ongoing prices are $179 and $249
- No state list is published, so eligibility is only confirmed at intake
- Cash-pay only, with no insurance billing
- No LegitScript or NABP seal visible on the site
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Buyers who want a genuinely flat all-dose compounded price and will ignore the intro-rate countdown.
Visit Bodi Envi Read the full Bodi Envi review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Bodi Envi does the reverse.
More on CoreAge Rx
More on Bodi Envi
Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.